Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084290" target="_blank" >RIV/00216224:14110/15:00084290 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00063352

Výsledek na webu

<a href="http://dx.doi.org/10.1111/jog.12764" target="_blank" >http://dx.doi.org/10.1111/jog.12764</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jog.12764" target="_blank" >10.1111/jog.12764</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging

Popis výsledku v původním jazyce

Aim An optimal surgical staging in the group of patients with the high-risk type of endometrial cancer is often limited by age and serious internal comorbidities. Therefore, in this study we focused on human epididymis protein 4 and its contribution to the preoperative differentiation of prognostically distinct groups of patients and to individualized surgical treatment as compared with cancer antigen (CA) 125 and imaging methods. Material and Methods The study included 115 patients with endometrioid adenocarcinoma diagnosed through endometrial biopsy. Before the final operation, blood sampling was performed for the determination of human epididymis protein 4 (HE4) and CA125 levels. Serum levels of both biomarkers were analyzed in relation to individual prognostic factors (stage of disease, depth of myometrial invasion, tumor grade, risk type of disease). Results In the case of HE4, we demonstrated a statistically significant difference (P &lt; 0.

Název v anglickém jazyce

Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging

Popis výsledku anglicky

Aim An optimal surgical staging in the group of patients with the high-risk type of endometrial cancer is often limited by age and serious internal comorbidities. Therefore, in this study we focused on human epididymis protein 4 and its contribution to the preoperative differentiation of prognostically distinct groups of patients and to individualized surgical treatment as compared with cancer antigen (CA) 125 and imaging methods. Material and Methods The study included 115 patients with endometrioid adenocarcinoma diagnosed through endometrial biopsy. Before the final operation, blood sampling was performed for the determination of human epididymis protein 4 (HE4) and CA125 levels. Serum levels of both biomarkers were analyzed in relation to individual prognostic factors (stage of disease, depth of myometrial invasion, tumor grade, risk type of disease). Results In the case of HE4, we demonstrated a statistically significant difference (P &lt; 0.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FK - Gynekologie a porodnictví

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Obstetrics and Gynaecology Research

ISSN

1341-8076

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

1644-1652

Kód UT WoS článku

000362677500021

EID výsledku v databázi Scopus

—